BR0201862A - Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos - Google Patents

Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos

Info

Publication number
BR0201862A
BR0201862A BR0201862-4A BR0201862A BR0201862A BR 0201862 A BR0201862 A BR 0201862A BR 0201862 A BR0201862 A BR 0201862A BR 0201862 A BR0201862 A BR 0201862A
Authority
BR
Brazil
Prior art keywords
seizures
compositions
treating
methods
preventing
Prior art date
Application number
BR0201862-4A
Other languages
English (en)
Inventor
Steven M Leventer
Robert Kucharik
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Publication of BR0201862A publication Critical patent/BR0201862A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA TRATAR OU PREVENIR CONVULSõES OU ATAQUES APOPLéCTICOS". A presente invenção refere-se às composições que compreendem S-tofisopam substancialmente livre de R-tofisopam, e aos métodos para tratar ou prevenir convulsões e/ou ataques apoplécticos compreendendo administração da composição aos pacientes em necessidade de tratamento por estes. Também fornecidas são composições e métodos para tratar ou prevenir convulsões e/ou ataques apoplécticos compreendendo administrar S-tofisopam substancialmente livre de R-tofisopam com outro anticonvulsivo.
BR0201862-4A 2001-05-18 2002-05-17 Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos BR0201862A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29202601P 2001-05-18 2001-05-18
US10/008,516 US6649607B2 (en) 2001-05-18 2001-11-08 Compositions and methods for treating or preventing convulsions or seizures

Publications (1)

Publication Number Publication Date
BR0201862A true BR0201862A (pt) 2003-03-25

Family

ID=26678275

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0201862-4A BR0201862A (pt) 2001-05-18 2002-05-17 Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos

Country Status (13)

Country Link
US (3) US6649607B2 (pt)
EP (1) EP1262184B1 (pt)
JP (2) JP2003012518A (pt)
AT (1) ATE293976T1 (pt)
AU (2) AU3702802A (pt)
BR (1) BR0201862A (pt)
CA (1) CA2381637A1 (pt)
DE (1) DE60203847T2 (pt)
ES (1) ES2241962T3 (pt)
GB (1) GB2377636A (pt)
IL (1) IL149134A (pt)
NZ (1) NZ518675A (pt)
WO (1) WO2002094189A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649607B2 (en) * 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
WO2004024163A1 (en) * 2002-09-13 2004-03-25 Motac Neuroscience Limited Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
ATE360415T1 (de) * 2002-09-17 2007-05-15 Motac Neuroscience Ltd Behandlung von dyskinesie
CA2510275A1 (en) * 2002-12-03 2004-08-19 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof
AU2003293405A1 (en) * 2002-12-03 2004-06-23 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
US7265106B2 (en) 2003-05-09 2007-09-04 Vela Aquisition Corporation Method for isolating (R)-tofisopam
CA2525273C (en) * 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
US20050288277A1 (en) * 2004-06-25 2005-12-29 Kucharik Robert F Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S)-2,3-benzodiazepine
US20070021412A1 (en) * 2003-05-16 2007-01-25 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S) 2,3-benzodiazepine
US20070032479A1 (en) * 2003-12-03 2007-02-08 Leventer Steven M Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
US20060111743A1 (en) * 2004-11-19 2006-05-25 Gurney Harry C Jr Method for arresting seizure activity
US7541355B2 (en) * 2005-05-23 2009-06-02 Vela Acquisition Corporation Conversion process for 2,3-benzodiazepine enantiomers
WO2007082546A1 (en) * 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
JP2008174495A (ja) * 2007-01-19 2008-07-31 Reverse Proteomics Research Institute Co Ltd 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
US9408852B2 (en) 2011-07-27 2016-08-09 Pharmos Corporation Method of lowering serum uric acid levels with (S)-tofisopam
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用
CN105363006A (zh) * 2015-12-16 2016-03-02 张景英 一种用于护理治疗小儿高热惊厥的中药药膏

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
ZA712798B (en) 1970-11-06 1972-02-23 Egyt Gyogyszervegyeszeti Gyar New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same
HU179018B (en) 1978-10-19 1982-08-28 Gyogyszerkutato Intezet Process for producing new 5h-2,3-benzodiazepine derivatives
HU186760B (en) 1981-03-12 1985-09-30 Gyogyszerkutato Intezet Process for preparing 3,4-dihydro-5h-2,3-aenzodiazepine derivatives
HU191698B (en) 1984-07-27 1987-03-30 Gyogyszerkutato Intezet Process for producing new 1-aryl-5h-2beta-benzodiazepines
HU198494B (en) 1986-08-15 1989-10-30 Gyogyszerkutato Intezet Process for producing new 3,4-dihydro-5h-2,3-benzodiazepine derivative and acid addition salts thereof, as well as pharmaceutical compositions comprising same
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
HU207055B (en) 1990-10-17 1993-03-01 Gyogyszerkutato Intezet Process for producing new 5h-2,3-benzodiazepine derivative and pharmaceutical compositions comprising same
US5519019A (en) 1990-12-21 1996-05-21 Gyogyszerkutato Intezet N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same
HU206719B (en) 1990-12-21 1992-12-28 Gyogyszerkutato Intezet Process for producing 1-/4-acylamino-phenyl/-7,8-methylenedioxy-5h-2,3-benzodiazepine derivatives, acid addicional salts and pharmaceutical compositions containing them
US5521174A (en) 1990-12-21 1996-05-28 Gyogyszerkutato Intezet Kv. N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of the skeletal musculature therewith
HU219778B (hu) 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
US5639751A (en) 1990-12-21 1997-06-17 Cyogyszerkutato Intezet Kft N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders
US6017965A (en) 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
HU219777B (hu) 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására
ES2170804T3 (es) 1994-08-31 2002-08-16 Lilly Co Eli Derivados de dihidro-2,3-benzodiazepina.
HU224435B1 (hu) 1995-02-09 2005-10-28 EGIS Gyógyszergyár Rt. Benzodiazepin-származékok, eljárás előállításukra, alkalmazásukra és ezeket tartalmazó gyógyászati készítmények
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
AU1451900A (en) 1998-10-27 2000-05-15 Vela Pharmaceuticals Inc. Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof
US6080736A (en) 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
US6649607B2 (en) * 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures

Also Published As

Publication number Publication date
US7078398B2 (en) 2006-07-18
DE60203847D1 (de) 2005-06-02
WO2002094189A3 (en) 2003-04-10
AU2002303817A1 (en) 2002-12-03
US6649607B2 (en) 2003-11-18
IL149134A0 (en) 2002-11-10
US20060166976A1 (en) 2006-07-27
WO2002094189A2 (en) 2002-11-28
JP2003012518A (ja) 2003-01-15
ES2241962T3 (es) 2005-11-01
CA2381637A1 (en) 2002-11-18
US20050075329A1 (en) 2005-04-07
DE60203847T2 (de) 2006-01-26
GB2377636A (en) 2003-01-22
IL149134A (en) 2007-06-17
EP1262184A1 (en) 2002-12-04
US20030055048A1 (en) 2003-03-20
AU3702802A (en) 2002-11-21
JP2007262096A (ja) 2007-10-11
GB0211247D0 (en) 2002-06-26
EP1262184B1 (en) 2005-04-27
NZ518675A (en) 2003-07-25
ATE293976T1 (de) 2005-05-15

Similar Documents

Publication Publication Date Title
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
CY1108706T1 (el) Ανοσορυθμιστης
ATE253063T1 (de) 5-ht1f-agonisten
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE506953T1 (de) 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
ATE337009T1 (de) Medizinische verwendung thyromimetischer verbindungen gegen haarausfall und zusammensetzungen
DE60234354D1 (de) Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
DOP2002000451A (es) Nuevas ciclohexilsulfonas (agentes terapéuticos)
ATE415965T1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
ID25478A (id) Agonis 5-ht1f
CY1106552T1 (el) Ενωσεις ισοχρωμανιου για την θεραπεια ανωμαλιων του κνς
BR0111785A (pt) Composições e métodos para tratamento de candidìase
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE60136706D1 (de) Ycin-acryloyl derivate und antimetabolische mitteln
ATE289510T1 (de) Sulfonylpyridazinone derivate zur behandlung von ischämischem gewebeschaden
ATE327240T1 (de) 2ß OXO-VORUSCHARIN UND DERIVATEN
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08G Application fees: restoration [chapter 8.7 patent gazette]
B25A Requested transfer of rights approved

Owner name: VELA ACQUISITION CORPORATION (US)

Free format text: TRANSFERIDO POR INCORPORACAO DE: VELA PHARMACEUTICALS, INC.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA DA PETICAO NO 020110009145/RJ DE 28/01/2011, O PEDIDO DE ALTERACAO DE NOME, POR AUSENCIA DE FUNDAMENTACAO LEGAL.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 12A E 13A ANUIDADES.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25E Requested change of name of applicant rejected

Owner name: VELA ACQUISITION CORPORATION (US)